Crispr Therapeutics Ag

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.crisprtx.com

Earnings Score
Moat Score

Market Cap $4.21B
PE -18
Debt $NaN
Cash $225.67M
EV $NaN
FCF -$191.20M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$239.59M
EBIT	-$236.47M
ROE	-12%
ROA	-10%
FCF	-$191.20M
Equity	$1.94B
Growth Stability	-2K%
PE	-17.58
PEG	-3.54
PB	2.17
P/FCF	-22.03
P/S	20.76
Price/Cash	0.05
Net Margins	-20K%
Op. Margins	-117%
Earnings CAGR	1%
Sales Growth QoQ	16%
Sales CAGR	46%
FCF CAGR	2%
Equity CAGR	42%
Earnings Stability	0
Earnings Growth YoY	-23%

Earnings Growth QoQ	-32%
Earnings CAGR 5Y	5%
Sales CAGR 5Y	15%
FCF CAGR 5Y	5%
Equity CAGR 5Y	13%
Earnings CAGR 3Y	36%
Sales CAGR 3Y	36%
Equity CAGR 3Y	-5%
Market Cap	$4.21B
Revenue	$202.83M
Assets	$2.26B
Cash	$225.67M
Shares Outstanding	83.91M
Earnings Score	6%
Moat Score	2%
Working Capital	1.85B
Current Ratio	21.64
Shares Growth 3y	3%
Equity Growth QoQ	-2%
Equity Growth YoY	12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

SEC Filings

Direct access to Crispr Therapeutics Ag (CRSP) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Crispr Therapeutics Ag compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Crispr Therapeutics Ag compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%

Stability 0%

loading chart...

Crispr Therapeutics Ag Discounted Cash Flow

Fully customizable DCF calculator online for Crispr Therapeutics Ag.

Years

Calculation mode

= -$2.1B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$191M	-$194M	-$197M	-$201M	-$204M	-$207M	-$211M	-$214M	-$217M	-$221M	-$225M	-$2.2B
DCF		-$177M	-$163M	-$151M	-$139M	-$129M	-$119M	-$110M	-$101M	-$94M	-$87M	-$866M
Value	-$2.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-10K%	-449%	-167%	-5K%	23%	-49K%	41%	-54K%	-41%	-20K%
ROA	-	-16%	-7%	-24%	-33%	6%	-19%	14%	-29%	-7%	-10%
ROE	-	89%	-10%	-36%	-42%	7%	-21%	16%	-35%	-8%	-12%

Bad Net Margins (-20.27K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-1.32	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-2K%	-	-2K%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-2K%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	2K%	694%	-92%	9K%	-100%	127K%	-100%	31K%	15%
Earnings YoY growth	-	268%	-10%	195%	141%	-141%	-622%	-208%	-272%	-76%	5%
Equity YoY growth	-	317%	-900%	-19%	109%	140%	77%	44%	-22%	0%	13%
FCF YoY growth	-	-	-196%	39%	27%	-150%	-614%	-278%	-217%	-49%	5%